FGFR3 and bladder transitional cell carcinoma: We found FGFR3–TACC3 to be the most recurrent fusion in BLCA (2.0%), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, 1.7%), and lung squamous cell carcinoma (LUSC, 1.2%).